Acadia Pharmaceuticals Inc [ACAD] stock prices are up 3.45% to $18.27 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ACAD shares have gain 24.97% over the last week, with a monthly amount glided 22.45%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Morgan Stanley downgraded its rating to Equal-Weight on August 07, 2024, and dropped its price target to $20. On June 27, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $31 on the stock. Needham reiterated its Buy rating and decreased its price target to $32 on March 12, 2024. Mizuho downgraded its rating to a Neutral and reduced its price target to $25 on March 12, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on January 30, 2024, and assigned it a price target of $40. In a note dated January 24, 2024, Needham upgraded an Buy rating on this stock but restated the target price of $37.
The stock price of Acadia Pharmaceuticals Inc [ACAD] has been fluctuating between $14.15 and $32.59 over the past year. Currently, Wall Street analysts expect the stock to reach $26.57 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $18.27 at the most recent close of the market. An investor can expect a potential return of 45.43% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
The Acadia Pharmaceuticals Inc [NASDAQ:ACAD] reported sales of 929.24M for trailing twelve months, representing a surge of 18.28%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.12%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.26 and Total Capital is 0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.89 points at the first support level, and at 17.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.68, and for the 2nd resistance point, it is at 19.09.
Ratios To Look Out For
It’s worth pointing out that Acadia Pharmaceuticals Inc [NASDAQ:ACAD]’s Current Ratio is 2.29. In addition, the Quick Ratio stands at 2.11 and the Cash Ratio stands at 0.45. Considering the valuation of this stock, the price to sales ratio is 3.36, the price to book ratio is 5.27 and price to earnings (TTM) ratio is 23.65.
Transactions by insiders
Recent insider trading involved Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER, that happened on Aug 19 ’24 when 9733.0 shares were sold. EVP, COO, HEAD OF COMMERCIAL, Teehan Brendan completed a deal on Aug 19 ’24 to sell 9534.0 shares. Meanwhile, CEO DAVIS STEPHEN sold 31747.0 shares on Aug 19 ’24.
